rogen is less complete and the oxygen concentration of inspired gas falls. Another type of machine, the membrane oxygen enricher (MOE), works on a different principle. This uses a semi permeable membrane that permits selective diffusion of oxygen and water, which produces gas of high humidity enriched to about 40% oxygen. This type of machine relies on a high flow rate to achieve adequate oxygenation of the patient. In an unpublished study of 23 hypoxic patients with chronic bronchitis and emphysema, the manufacturers have shown that to achieve a given arterial oxygen saturation (Sao2) the MOE must deliver 40% oxygen at a flow rate three times greater than the flow rate of 100% oxygen that is required to produce this Sao2.
Long term domiciliary oxygen treatment for 15 or more hours daily can prolong the survival of patients with hypoxic chronic bronchitis and emphysema.' 2 The costs are considerable, but oxygen concentrators are the cheapest3 and probably the most convenient way to provide this form of treatment. Most modem concentrators are of the molecular sieve (MS) type, using columns of synthetic aluminium silicate (zeolite) to adsorb nitrogen from room air, so producing an inspired gas with a high concentration of oxygen (>90% at low flow rates) with small amounts of trace gases. As the flow rate is increased a greater volume of gas passes through the molecular sieve, and the time spent in contact with the aluminium silicate is less, so that adsorption of nit-rogen is less complete and the oxygen concentration of inspired gas falls. Another type of machine, the membrane oxygen enricher (MOE), works on a different principle. This uses a semi permeable membrane that permits selective diffusion of oxygen and water, which produces gas of high humidity enriched to about 40% oxygen. This type of machine relies on a high flow rate to achieve adequate oxygenation of the patient. In an unpublished study of 23 hypoxic patients with chronic bronchitis and emphysema, the manufacturers have shown that to achieve a given arterial oxygen saturation (Sao2) the MOE must deliver 40% oxygen at a flow rate three times greater than the flow rate of 100% oxygen that is required to produce this Sao2. We 
Methods
The technical performance of all the concentrators was assessed in the laboratory in two sets of tests.
(1) During four weeks of continuous running at a flow rate of 21 min-' (6 1 min-' for OE-4E) we measured the oxygen concentration and humidity of the inspired gas and the temperature of the concentrator exhaust gas. In addition, the MS concentrators were run continuously for a further five days, each day the oxygen concentration of the inspired Technical and clinical assessment of oxygen concentrators gas being measured after one hour of flow at 1, 2, 3, 4 and 5 1 min-'. For the rest of each 24 hour period the concentrators were run at a flow rate of 2 l min-' .
The clinical performance of four concentrators (the Mini 02 was not available at the time of the study) was assessed by measuring the rise in arterial oxygen saturation (Sao2) produced in 20 hypoxic patients (1 2M, 8F; age 47-93, mean 67 years; FEV1 0.3-3.1, mean 0.91; VC 0.6-4.2, mean 1.91; Pao2 4.9-9.0, mean 7.1 kPa; Paco2 3.3-8.9, mean 6.0 kPa) who inspired from each machine at 2 1 min-' (6 1 min-' for OE-4E) through nasal prongs. The order for the concentrators studied in the 20 patients was assigned randomly, and Sao2 was allowed to stabilise when patients were breathing room air between each period of gas delivery.
Home visits were made to 10 patients receiving domiciliary oxygen treatment on three separate occasions. At each visit their Sao2 was measured when they were inspiring from the concentrator through nasal prongs, and inspired gas was collected from the concentrator to measure the oxygen concentration.
Measurement of oxygen concentration was carried out with a Sybron/Taylor Servomex 02 analyser but we do not know whether this fall in the oxygen delivered will have any significant clinical effect (in the domiciliary part of this study the lowest oxygen concentrationi delivered by a concentrator was 89.8%, but at the same time the patient's Sao2 was 93%). The OE-4E delivered gas with more variable oxygen concentrations, but this machine was affected more by changes in room temperature than the others. Consistently high humidity (mean 90.9%) was'achieved by the OE-4E (table 2) .
(2) The oxygen concentration of inspired gas fell as flow rate increased with all the MS concentrators, but at flow rates of over 2 1 min-' the two newer machines (MINI DeVO2, Roomate III) delivered higher oxygen concentrations (fig 3) . The Mini 02 iS a machine intended for use at flow rates of less than 3 1 min-' and it delivers lower oxygen concentrations' than the other MS concentrators at flow rates of 3 and 41 min-'.
CLINICAL PERFORMANCE
Each patient achieved a rise in Sao2 when breathing Gould, Scott, Hayhurst, Flenley gas from each concentrator (fig 4), figure 5 .
Discussion
Previous studies4 have shown that concentrators are an acceptable means of providing long term domiciliary oxygen treatment. Since the time of those studies technology has advanced, today's concentrators being smaller and lighter yet having improved performance. A concentrator that is intended for long term domiciliary use must be not only reliable and able to deliver high oxygen con- centrations consistently but also acceptable to the patient. Long term reliability can be assessed only from the service record in actual use, but from a study of this kind we are able to make some assessment of the other two features. Acceptability to patients was high for the four MS concentrators studied. They are simple to operate and quiet when running, and they give out warm exhaust gas, which is unlikely to be unacceptable. The newer MS concentrators (MINI DeVO2, Roomate III) have the added advantage of reduced size and weight, though this will be unimportant if the machine is not intended for use in more than one place. The MS concentrators all produce consistently high oxygen concentrations at flow rates of up to 2 1 min-', but at flow rates of 3 and 4 1 min-' the MINI DeVO2 and Roomate III deliver higher oxygen concentrations than the Econo2 and Mini 02. As shown in the laboratory and domiciliary clinical studies, all patients should achieve a satisfactory level of oxygenation once the oxygen flow rate has been set appropriately.
It is probably inappropriate to compare the OE-4E directly with the MS concentrators we have studied, as it is a totally different type of machine, which works by a different principle, and is particularly intended for patients in whom humidification of inspired oxygen enriched gas is necessary. These might include patients with cystic fibrosis or bronchiectasis or those with a long term tracheostomy, but we know of no long term studies of the use of such a device in these patients.
The maximal flow rate achieved by the OE-4E is dependent on room temperature, ranging from 61min-' at 18°C to 101min-' at 35°C; but as temperature rises the concentration of oxygen in the inspired gas falls, so that the potential of this machine to improve a patient s oxygenation is relatively inflexible by comparison with a molecular sieve concentrator. The machine we studied achieved a maximal flow rate of 61 min-', and in Gould, Scott, Hayhurst, Flenley several of the hypoxic patients studied a satisfactory Sao2 was not achieved at this flow rate. Given that the objective of the OE-4E is to produce gas of high humidity that is moderately enriched in oxygen, it does achieve its aim, but owing to its flow rate limitations it would not be suitable for most hypoxic patients who are considered for long term oxygen treatment in Britain.
In summary, we have found that, although the membrane oxygen enricher that we studied, the OE-4E, may have a specific part to play in treating selected patients, it would not be suitable for most hypoxic patients, who do not require the high levels of humidity it delivers and who would be served better by a molecular sieve concentrator, particularly if they are severely hypoxic and require high flow rates of oxygen to achieve adequate oxygenation. The four molecular sieve concentrators studied are all suitable for domiciliary use, being simple to operate and consistent in performance; but the two "state of the art' machines, the MINI DeVO2 and the Roomate III, are smaller, lighter, and more portable and also perform well, delivering high oxygen concentrations at flow rates of up to 4 1 min-'.
